Related Experiment Video
Updated: Oct 13, 2025
09:41
Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform
Published on: February 25, 2021
24.0K
Lipid Nanoparticle-mRNA Formulations for Therapeutic Applications
Chang Wang1, Yuebao Zhang1, Yizhou Dong1,2
1Division of Pharmaceutics & Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States.
Accounts of Chemical Research
|November 18, 2021
Summary
Lipid nanoparticles (LNPs) are advancing mRNA therapeutics for various diseases. Researchers are developing novel LNPs and engineering mRNA for improved delivery, efficiency, and therapeutic applications beyond COVID-19 vaccines.
Area of Science:
- Biotechnology and Pharmaceutical Sciences
- Nanomedicine and Drug Delivery Systems
- Molecular Biology and Genetic Engineering
Background:
- Lipid nanoparticles (LNPs) have proven effective for mRNA delivery, notably in COVID-19 vaccines.
- mRNA therapeutics show promise for protein replacement, genome editing, and cancer immunotherapy.
- Challenges remain in developing efficient, low-toxicity delivery systems and optimizing mRNA for diverse cell types and therapeutic goals.
Purpose of the Study:
- To summarize recent advances in designing and developing novel lipid-based delivery systems for mRNA therapeutics.
- To highlight progress in engineering mRNA molecules for enhanced pharmaceutical properties and protein expression.
- To showcase the application of integrated LNP and mRNA technologies in treating various diseases.
Main Methods:
- Design and synthesis of novel ionizable lipid-like molecules, including benzene-core structures and biodegradable ester-containing lipids.
- Development of biomimetic lipids such as vitamin-derived, chemotherapeutic-conjugated, phospholipids, and glycolipids.
- Optimization of mRNA chemistry through modified nucleotides (e.g., pseudouridine) and engineering of 5' and 3' untranslated regions (UTRs).
Main Results:
- Identification of a lead ionizable lipid-like compound (TT3) for effective in vitro and in vivo mRNA delivery.
- Demonstrated enhancement of protein expression through mRNA chemical modifications and UTR engineering.
- Successful application of LNP-mRNA formulations in preclinical models for hemophilia, infectious diseases, and cancer immunotherapy.
Conclusions:
- Lipid-mRNA nanoparticle formulations are crucial for public health, as evidenced by their role in the COVID-19 pandemic.
- Continued integration of chemistry, engineering, materials science, pharmaceutical sciences, and medicine is vital for clinical translation.
- Further development promises broader clinical applications of LNP-mRNA technology for diverse human health benefits.
